Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Okebo
Overview
What is Okebo?
Doxycycline is a broad-spectrum antibacterial synthetically derived from oxytetracycline. Okebo (Doxycycline monohydrate USP) Capsules, 100 mg, 75 mg, and 50 mg capsules contain doxycycline monohydrate equivalent to 100 mg, 75 mg, or 50 mg of doxycycline for oral administration. The chemical designation of the light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline.
Structural formula:
Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.
Inert ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose and sodium starch glycolate Type A Potato. Hard gelatin capsule contains black iron oxide, gelatin, red iron oxide, titanium dioxide and yellow iron oxide. The capsules are printed with edible ink containing black iron oxide, potassium hydroxide, propylene glycol, shellac and titanium dioxide.
What does Okebo look like?
What are the available doses of Okebo?
Sorry No records found.
What should I talk to my health care provider before I take Okebo?
Sorry No records found
How should I use Okebo?
To reduce the development of drug-resistant bacteria and maintain effectiveness of Okebo and other antibacterial drugs,
Okebo should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Doxycycline is indicated for the treatment of the following infections:
Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:
Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.
Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:
Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:
When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections:
In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides.
In severe acne, doxycycline may be useful adjunctive therapy.
THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.
What interacts with Okebo?
This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.
What are the warnings of Okebo?
The use of drugs of the tetracycline class, including doxycycline, during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use of doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g. anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including Okebo. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and Okebo should be avoided because isotretinoin is also known to cause pseudotumor cerebri.
Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.
All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.
Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.
The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.
Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.
What are the precautions of Okebo?
General
As with other antibacterial preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, Okebo should be discontinued and appropriate therapy instituted.
Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy when indicated.
Prescribing Okebo in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Information for Patients
All patients taking doxycycline should be advised:
–to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (e.g., skin eruptions, etc.) occurs. Sunscreen or sunblock should be considered. (See .)
–to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration. (See .)
–that the absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. (See .)
–that the absorption of tetracyclines is reduced when taking bismuth subsalicylate. (See .)
–not to use outdated or poorly stored doxycycline.
–that the use of doxycycline might increase the incidence of vaginal candidiasis.
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
Patients should be counseled that antibacterial drugs including Okebo should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Okebo is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Okebo or other antibacterial drugs in the future.
Laboratory Tests
In venereal disease when coexistent syphilis is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least four months.
In long-term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed.
Drug Interactions
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
Concurrent use of tetracycline may render oral contraceptives less effective.
Drug/Laboratory Test Interactions
False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals to evaluate the carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with related antibacterial, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in mammalian cell assays have been reported for related antibacterial (tetracycline, oxytetracycline). Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.
Pregnancy
Teratogenic Effects.
Pregnancy Category D
There are no adequate and well-controlled studies on the use of doxycycline in pregnant short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS -the Teratogen Information System -concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk.
A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. (Sixty-three [0.19%] of the controls and 56 [0.30%] of the cases were treated with doxycycline.) This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with neural tube defect based on only two exposed cases.
A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age.
Labor and Delivery
The effect of tetracyclines on labor and delivery is unknown.
Nursing Mothers
Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines, including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown. Because of the potential for adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See .)
Pediatric Use:
Because of the effects of drugs of the tetracycline –class, on tooth development and growth, use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g. anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies. .
What are the side effects of Okebo?
Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines.
Gastrointestinal
Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region, and pancreatitis. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See .)
Skin
Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme have been reported. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See .)
Renal Toxicity
Rise in BUN has been reported and is apparently dose related. (See .)
Hypersensitivity Reactions
Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus.
Blood
Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported with tetracyclines.
Other
Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines. (See .)
When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function are known to occur.
What should I look out for while using Okebo?
This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.
The use of drugs of the tetracycline class, including doxycycline, during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use of doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g. anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.
Clostridium difficile
C. difficile
C. difficile
C. difficile
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including Okebo. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and Okebo should be avoided because isotretinoin is also known to cause pseudotumor cerebri.
Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.
All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.
Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.
The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.
Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.
What might happen if I take too much Okebo?
In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life, and it would not be of benefit in treating cases of overdosage.
How should I store and handle Okebo?
Vials should be stored in a refrigerator at 2° to 8°C (36° to 46°F). Vials may be transferred to 25°C (77°F) [see USP Controlled Room Temperature]; for up to 2 months. Upon transfer, vial cartons must be marked by the dispensing pharmacist with a "DISCARD BY" date (2 months from the transfer date or the labeled expiration date, whichever comes first). Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M71" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 50 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg is available in: Bottle of 100 capsules NDC 69482-400-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg are brown opaque cap and light yellow opaque body imprinted with "LU" on cap in white ink and "M72" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 75 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg is available in: Bottle of 100 capsules NDC 69482-475-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M73" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 100 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg is available in: Bottle of 50 capsules NDC 69482-450-50Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature]. Protect from light.Dispense in a tight, light-resistant container as defined in the USP/NF.Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M71" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 50 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg is available in: Bottle of 100 capsules NDC 69482-400-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg are brown opaque cap and light yellow opaque body imprinted with "LU" on cap in white ink and "M72" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 75 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg is available in: Bottle of 100 capsules NDC 69482-475-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M73" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 100 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg is available in: Bottle of 50 capsules NDC 69482-450-50Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature]. Protect from light.Dispense in a tight, light-resistant container as defined in the USP/NF.Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M71" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 50 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg is available in: Bottle of 100 capsules NDC 69482-400-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg are brown opaque cap and light yellow opaque body imprinted with "LU" on cap in white ink and "M72" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 75 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg is available in: Bottle of 100 capsules NDC 69482-475-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M73" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 100 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg is available in: Bottle of 50 capsules NDC 69482-450-50Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature]. Protect from light.Dispense in a tight, light-resistant container as defined in the USP/NF.Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M71" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 50 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg is available in: Bottle of 100 capsules NDC 69482-400-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg are brown opaque cap and light yellow opaque body imprinted with "LU" on cap in white ink and "M72" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 75 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg is available in: Bottle of 100 capsules NDC 69482-475-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M73" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 100 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg is available in: Bottle of 50 capsules NDC 69482-450-50Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature]. Protect from light.Dispense in a tight, light-resistant container as defined in the USP/NF.Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M71" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 50 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg is available in: Bottle of 100 capsules NDC 69482-400-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg are brown opaque cap and light yellow opaque body imprinted with "LU" on cap in white ink and "M72" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 75 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg is available in: Bottle of 100 capsules NDC 69482-475-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M73" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 100 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg is available in: Bottle of 50 capsules NDC 69482-450-50Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature]. Protect from light.Dispense in a tight, light-resistant container as defined in the USP/NF.Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M71" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 50 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg is available in: Bottle of 100 capsules NDC 69482-400-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg are brown opaque cap and light yellow opaque body imprinted with "LU" on cap in white ink and "M72" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 75 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg is available in: Bottle of 100 capsules NDC 69482-475-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M73" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 100 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg is available in: Bottle of 50 capsules NDC 69482-450-50Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature]. Protect from light.Dispense in a tight, light-resistant container as defined in the USP/NF.Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M71" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 50 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg is available in: Bottle of 100 capsules NDC 69482-400-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg are brown opaque cap and light yellow opaque body imprinted with "LU" on cap in white ink and "M72" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 75 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg is available in: Bottle of 100 capsules NDC 69482-475-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M73" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 100 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg is available in: Bottle of 50 capsules NDC 69482-450-50Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature]. Protect from light.Dispense in a tight, light-resistant container as defined in the USP/NF.Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M71" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 50 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 50 mg is available in: Bottle of 100 capsules NDC 69482-400-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg are brown opaque cap and light yellow opaque body imprinted with "LU" on cap in white ink and "M72" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 75 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 75 mg is available in: Bottle of 100 capsules NDC 69482-475-99Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg are brown opaque cap and yellow opaque body imprinted with "LU" on cap in white ink and "M73" on the body in black ink filled with light yellow to grey colored blend.Each capsule contains doxycycline monohydrate USP equivalent to 100 mg doxycycline. Okebo™ (Doxycycline Monohydrate USP) Capsules, 100 mg is available in: Bottle of 50 capsules NDC 69482-450-50Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature]. Protect from light.Dispense in a tight, light-resistant container as defined in the USP/NF.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.
Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers averaged the following serum concentration values:
Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may fall as low as 1 to 5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function.
Hemodialysis does not alter serum half-life.
Non-Clinical Toxicology
This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.The use of drugs of the tetracycline class, including doxycycline, during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use of doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g. anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.
Clostridium difficile
C. difficile
C. difficile
C. difficile
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including Okebo. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and Okebo should be avoided because isotretinoin is also known to cause pseudotumor cerebri.
Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.
All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.
Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.
The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.
Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.
Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.
The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
Concurrent use of tetracycline may render oral contraceptives less effective.
As with other antibacterial preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, Okebo should be discontinued and appropriate therapy instituted.
Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy when indicated.
Prescribing Okebo in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
517Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).